Emergent BioSolutions Acquires Trubion

US biotechnology company Emergent BioSolutions has signed a definitive US$98mn agreement to acquire Trubion Pharmaceuticals, a biopharmaceutical company specialising in protein therapeutics. Emergent BioSolutions, which specialises in vaccines and antibody therapies, will benefit from the deal by diversifying its product pipeline beyond infectious diseases into the high-growth areas of oncology and autoimmunity, as well as broadening its monoclonal antibody-based therapeutic

To read the full article, please choose one of the following options: